Naperville, IL -- (SBWIRE) -- 03/10/2015 -- Reportstack, provider of premium market research reports announces the addition of Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019 market report to its offering

About Acquired Orphan Blood Diseases Therapeutics

Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. The acquired orphan blood diseases are developed in the blood after the post fetal life; they are not caused because of genetic reasons. The major orphan blood diseases that contribute to acquired orphan blood diseases are the following: ITP, MDS, MF PNH, and PV.   

Analysts forecast the Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS.

Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Acquired Orphan Blood Diseases Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

- Americas

- APAC

- EMEA     

Key Vendors

- Alexion Pharmaceuticals

- Amgen

- Celgene

- F. Hoffmann- La Roche

- GlaxoSmithKline

- Incyte

Other Prominent Vendors

- Cyclacel  Pharmaceuticals

- CTI Biopharma (Cell Therapeutics)

- Eli Lilly

- Gilead Sciences

- Onconova Therapeutics

- MebVax Therapeutics

- Novartis

- Sanofi

- Shire Pharmaceuticals

- S* Bio Pte

Market Driver

- Exemption from Pricing Obstacle

- For a full, detailed list, view our report

Market Challenge

- Companies Hesitant to Invest in Rare Diseases Therapeutics

- For a full, detailed list, view our report

Market Trend

- Benefit from Untapped Market

- For a full, detailed list, view our report

Key Questions Answered in this Report

- What will the market size be in 2019 and what will the growth rate be?

- What are the key market trends?

- What is driving this market?

- What are the challenges to market growth?

- Who are the key vendors in this market space?

- What are the market opportunities and threats faced by the key vendors?

- What are the strengths and weaknesses of the key vendors?

Complete report is available
http://www.reportstack.com/product/194186/global-acquired-orphan-blood-diseases-therapeutics-market-2015-2019.html

Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604